Plain-English translation of NCT07089706 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial evaluated the safety and immune response of mRNA-1283, an updated COVID-19 vaccine designed to protect against newer virus variants. The study was conducted in two parts and included older adults (65+) and younger people (12-64) who had at least one health condition that increased their risk of severe COVID-19. Researchers tracked how well the medication worked and what side effects participants experienced.
As the COVID-19 virus continues to change and evolve, vaccines need to be updated to match new variants and keep people protected. This trial tested whether this updated formulation would be safe and effective for vulnerable populations.
Participants received a single injection of the updated vaccine and were monitored for safety and immune response. The trial included two parts—Part A was discontinued early, and Part B involved more detailed safety follow-up with longer monitoring periods and tracking of common vaccine side effects. Participants attended study visits and reported any reactions or health changes during the follow-up period.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States